Search research articles
Contact Us
Filters
Showing results (121-130 of 145) with videos related to
Page
of 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Lancet (London, England)
|
February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
David M Gershenson, Austin Miller, William E Brady, et al.
The New England Journal of Medicine
|
December 30, 2011
A phase 3 trial of bevacizumab in ovarian cancer
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer
Robert L Hollis, Austin Miller, Heather A Lankes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 20, 2021
Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Ailith Ewing, Alison Meynert, Michael Churchman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Oxford Classic-defined EMT risk stratification of High Grade Serous Ovarian cancer for guiding treatment decisions
Lena Rai, Antonella Ravaggi, Eliana Bignotti, et al.
International Journal of Cancer
|
December 19, 2022
Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study
Citadel J Cabasag, Melina Arnold, Mark Rutherford, et al.
Gynecologic Oncology
|
January 24, 2020
Low-grade serous ovarian cancer: State of the science
Brian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study
Joo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 145) with videos related to
Sort By:
Page
of 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Lancet (London, England)
|
February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
David M Gershenson, Austin Miller, William E Brady, et al.
The New England Journal of Medicine
|
December 30, 2011
A phase 3 trial of bevacizumab in ovarian cancer
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer
Robert L Hollis, Austin Miller, Heather A Lankes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 20, 2021
Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Ailith Ewing, Alison Meynert, Michael Churchman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Oxford Classic-defined EMT risk stratification of High Grade Serous Ovarian cancer for guiding treatment decisions
Lena Rai, Antonella Ravaggi, Eliana Bignotti, et al.
International Journal of Cancer
|
December 19, 2022
Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study
Citadel J Cabasag, Melina Arnold, Mark Rutherford, et al.
Gynecologic Oncology
|
January 24, 2020
Low-grade serous ovarian cancer: State of the science
Brian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study
Joo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Page
of 15